BIMP Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details

BIMP fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (31.7x) is below the Medical Equipment industry average (35.5x)

Earnings are forecast to grow 12.62% per year

Earnings have grown 2.3% per year over the past 5 years

Risk Analysis

No risks detected for BIMP from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

bioMérieux S.A. Competitors

Smith & Nephew

LSE:SN.

UK£9.4b

NIOX Group

AIM:NIOX

UK£266.9m

ConvaTec Group

LSE:CTEC

UK£5.3b

EKF Diagnostics Holdings

AIM:EKF

UK£96.4m

Price History & Performance

Summary of share price highs, lows and changes for bioMérieux
Historical stock prices
Current Share Price	€114.75
52 Week High	€119.45
52 Week Low	€88.65
Beta	0.50
1 Month Change	3.99%
3 Month Change	-0.48%
1 Year Change	16.59%
3 Year Change	30.61%
5 Year Change	-8.64%
Change since IPO	445.91%

Recent updates

Shareholder Returns

	BIMP	GB Medical Equipment	GB Market
7D	-2.0%	-1.3%	-0.3%
1Y	16.6%	0.7%	-0.4%

Return vs Industry: BIMP exceeded the UK Medical Equipment industry which returned 0.7% over the past year.

Return vs Market: BIMP exceeded the UK Market which returned -0.4% over the past year.

Price Volatility

Is BIMP's price volatile compared to industry and market?
BIMP volatility
BIMP Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.6%
Market Average Movement	5.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine BIMP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1963	14,451	Pierre Boulud	www.biomerieux.com

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BIMP fundamental statistics
Market cap	€13.72b
Earnings (TTM)	€432.20m
Revenue (TTM)	€3.98b

31.7x

P/E Ratio

3.4x

P/S Ratio

Is BIMP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIMP income statement (TTM)
Revenue	€3.98b
Cost of Revenue	€1.76b
Gross Profit	€2.22b
Other Expenses	€1.78b
Earnings	€432.20m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Sep 04, 2025

Earnings per share (EPS)	3.66
Gross Margin	55.66%
Net Profit Margin	10.86%
Debt/Equity Ratio	7.6%

How did BIMP perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

25%

Payout Ratio

Does BIMP pay a reliable dividends?

See BIMP dividend history and benchmarks

When do you need to buy BIMP by to receive an upcoming dividend?
bioMérieux dividend dates
Ex Dividend Date	Jun 09 2025
Dividend Pay Date	Jun 11 2025
Days until Ex dividend	27 days
Days until Dividend pay date	29 days

Does BIMP pay a reliable dividends?

See BIMP dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 10:01
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bioMérieux S.A. is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Armelle Moulin	AlphaValue
Gaurav Jain	Barclays
Thomas Jones	Berenberg